Ceres Brain Therapeutics
Description
Created in 2019 as a spin-off of the French CEA, one of the leading research organizations in Europe, Ceres Brain Therapeutics is a clinical stage pharmaceutical company based in the Paris Brain Institute (ICM), France. Multiple asset company, Ceres first program consists in the development of CBT101, a breakthrough therapy to tackle the severe metabolic deficits of the neurons associated with various neurological diseases. CBT101 leverages the multiple properties of the creatine (anti-oxidant, anti-inflammatory, anti-apoptoctic and energy buffer) to exert its neuroprotective effects on the neurons. With remarkable proofs of efficacy in animal models, CBT101 is expected to slow down / stop disease progression and improve in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis. CBT101 providing creatine to neurons, may also reverse symptoms of children presenting with Brain Creatine Transporter Deficiency Syndrome (CTD), a rare disease leading to severe intellectual deficiency, autism and seizure. CBT101 was granted Orphan Drug Designation in CTD by FDA and EMA
Company members
Thomas Joudinaud, MD, PhD ; Henri Bénech, PharmD, PhD ; Aloise Mabondzo, PhD ; The CEA
